iCad AI tech accurately predicts breast cancer risk, provides heart disease insights

iCad (Nasdaq:ICAD) today announced plans to present new studies validating its AI-powered ProFound Breast Health Suite.

ProFound helps to uncover hidden heart or vascular disease and predict a woman’s risk for developing breast cancer in the next 1-2 years. The platform can screen a single mammogram for two of the top causes of death for women. iCad designed it to improve accuracy, streamline clinical workflow and deliver results more quickly.

The company plans to present its findings at RSNA23.

“The ProFound Breast Health Suite significantly increases cancer detection rates with up to 2x enhanced clinical performance compared to other AI platforms, and reduces the rate of false positive results while accurately evaluating a woman’s breast density and cancer risk,” said Dana Brown, president and CEO of iCad, Inc. “Our growing body of important research illustrates the potential our newest solution, ProFound Heart Health, holds for the assessment of…

Read more
  • 0

How Google and iCAD will partner to advance AI mammography

iCAD’s AI for digital breast tomosynthesis provides a case score for each detection. (Image courtesy of iCAD)

iCAD will help Google Health get its AI mammography technology into clinical practice, while Google will help iCAD improve its algorithms and reach more patients through the cloud.

Google and cancer detection developer iCAD are teaming up on the development and commercialization of artificial intelligence (AI) for detecting breast cancer.

It’s Google Health’s first partnership with a mammography AI provider. The development and commercialization agreement is Google Health’s first deal to introduce its breast imaging AI into clinical practice through iCAD’s portfolio of AI products.

RELATED: How the cloud tools behind Google Maps and Photos can advance medtech

Nashua, New Hampshire-based iCAD (Nasdaq:ICAD) is licensing Google’s AI technology for breas…

Read more
  • 0